FLNA net incomeQ3 2026-$10.73M
FLNA net income was -$10.73M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$10.81M a year earlier. For the full fiscal 2025 it was -$90.97M, compared with -$24.34M in fiscal 2024.
Filana Therapeutics Inc. (FLNA) financials
For the twelve months ended Sep 30, 2026, Filana Therapeutics Inc. reported -$42.20M of net income.
- Net income, TTM
- -$42.20M
- Cash
- $46.99M
- Market cap
- $24.2M
FY2016FY2025
FY2016FY2025
FLNA revenue and earnings growth
FLNA EPSQ4 2025-$0.26
FLNA diluted EPS was -$0.26 in fiscal Q4 2025 (ended Dec 31, 2025), compared with -$0.58 a year earlier. For the full fiscal 2025 it was -$1.88, compared with -$1.46 in fiscal 2024.
FLNA free cash flowQ3 2026-$6.13M
FLNA free cash flow was -$6.13M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$6.30M a year earlier. For the full fiscal 2025 it was -$32.83M, compared with -$117.03M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $26.59M | $69.64M | $89.42M | $68.03M | $24.81M | - | - | $2.97M | $7.62M | $9.18M |
| Selling, general and admin | $68.80M | $71.81M | $16.53M | $11.99M | $8.05M | $3.74M | $3.39M | $3.69M | $4.33M | $5.78M |
| Operating income | -$95.39M | -$141.45M | -$105.96M | -$80.02M | -$32.87M | -$6.45M | -$4.96M | -$6.66M | -$11.95M | -$14.96M |
| Income tax | $0 | $0 | - | - | - | - | - | - | - | - |
| Net income | -$90.97M | -$24.34M | -$97.22M | -$76.25M | -$32.38M | -$6.33M | -$4.63M | -$6.56M | -$11.91M | -$14.85M |
| EPS, basic | -$1.88 | -$0.53 | -$2.32 | -$1.90 | -$0.82 | -$0.24 | -$0.27 | -$0.61 | -$1.82 | -$2.28 |
| EPS, diluted | -$1.88 | -$1.46 | -$2.32 | -$1.90 | -$0.82 | -$0.24 | -$0.27 | -$0.61 | -$1.82 | -$2.28 |
| Diluted shares | 48.3M | 46.6M | 41.9M | 40.2M | 39.4M | 26.1M | 17.4M | 10.7M | 6.5M | 6.5M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $95.50M | $128.57M | $121.14M | $201.01M | $233.44M | $93.51M | $23.08M | $19.81M | $10.48M | $16.61M |
| Short-term investments | - | - | - | - | - | - | - | - | - | $2.10M |
| Current assets | $97.71M | $136.53M | $129.63M | $211.23M | $244.48M | $93.99M | $23.35M | $20.04M | $10.66M | $19.07M |
| Total assets | $118.36M | $157.53M | $151.66M | $234.83M | $266.78M | $94.30M | $23.49M | $20.14M | $10.83M | $19.30M |
| Current liabilities | $43.83M | $11.75M | $14.20M | $7.06M | $12.53M | $1.86M | $1.39M | $511.0K | $1.13M | $665.0K |
| Total liabilities | $43.95M | $11.83M | $14.20M | $7.29M | $12.87M | $2.10M | $1.39M | $511.0K | $1.13M | $665.0K |
| Shareholders' equity | $74.40M | $145.70M | $137.47M | $227.54M | $253.91M | $92.20M | $22.10M | $19.63M | $9.70M | $18.64M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$32.25M | -$116.93M | -$82.03M | -$77.51M | -$30.20M | -$5.38M | -$2.51M | -$4.77M | -$8.24M | -$12.23M |
| Capital expenditures | $581.0K | $103.0K | $414.0K | $2.71M | $22.21M | - | $18.0K | - | - | $75.0K |
| Free cash flow | -$32.83M | -$117.03M | -$82.44M | -$80.23M | -$52.41M | - | -$2.53M | - | - | -$12.31M |
| Investing cash flow | -$581.0K | -$103.0K | -$414.0K | -$2.71M | -$22.21M | $360.0K | -$18.0K | - | $2.10M | -$2.17M |
| Financing cash flow | -$239.0K | $124.47M | $2.56M | $47.80M | $192.34M | $75.45M | $5.81M | $14.10M | - | -$284.0K |
| Stock-based compensation | $19.58M | $16.29M | $4.59M | $2.07M | $1.76M | $988.0K | $1.30M | $2.39M | $2.97M | $4.33M |
| Depreciation and amortization | - | - | - | - | - | $22.0K | $58.0K | $69.0K | $68.0K | $58.0K |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on equity | -122.3% | -16.7% | -70.7% | -33.5% | -12.8% | -6.9% | -21.0% | -33.4% | -122.8% | -79.7% |
| Return on assets | -76.9% | -15.5% | -64.1% | -32.5% | -12.1% | -6.7% | -19.7% | -32.6% | -110.0% | -76.9% |
| Current ratio | 2.23 | 11.62 | 9.13 | 29.91 | 19.51 | 50.40 | 16.83 | 39.22 | 9.42 | 28.68 |
Income statement
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $3.87M | $3.30M | $4.54M | $3.85M | $3.96M | $5.12M | $13.67M | $20.53M | $17.68M | $15.20M | $16.23M | $18.73M |
| Selling, general and admin | $7.41M | $6.09M | $6.62M | $9.70M | $7.91M | $40.28M | $10.92M | $8.96M | $12.95M | $46.20M | $3.70M | $4.06M |
| Operating income | -$11.27M | -$9.39M | -$11.17M | -$13.55M | -$11.86M | -$45.39M | -$24.59M | -$29.49M | -$30.62M | -$61.40M | -$19.93M | -$22.79M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | - |
| Net income | -$10.73M | -$8.60M | -$10.33M | -$12.54M | -$10.81M | -$44.22M | -$23.40M | -$27.60M | -$27.94M | $6.16M | $25.04M | -$20.92M |
| EPS, basic | -$0.22 | -$0.18 | -$0.21 | -$0.26 | -$0.22 | -$0.92 | -$0.48 | -$0.66 | -$0.58 | $0.13 | $0.58 | -$0.50 |
| EPS, diluted | - | - | - | -$0.26 | -$0.22 | -$0.92 | -$0.48 | -$0.58 | -$0.58 | $0.13 | -$0.43 | -$0.50 |
| Diluted shares | - | - | - | - | 48.3M | 48.3M | 48.3M | - | 48.0M | 46.2M | 44.1M | - |
Balance sheet
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $46.99M | $82.68M | $86.57M | $95.50M | $106.08M | $112.38M | $117.33M | $128.57M | $148.98M | $207.29M | $124.17M | $121.14M |
| Current assets | $80.06M | $83.72M | $87.96M | $97.71M | $108.91M | $114.82M | $120.15M | $136.53M | $202.55M | $222.12M | $134.00M | $129.63M |
| Total assets | $100.06M | $103.90M | $108.37M | $118.36M | $129.73M | $135.38M | $140.93M | $157.53M | $223.75M | $243.57M | $155.72M | $151.66M |
| Current liabilities | $41.95M | $40.16M | $40.12M | $43.83M | $48.05M | $47.33M | $13.24M | $11.75M | $57.03M | $54.59M | $77.12M | $14.20M |
| Total liabilities | $42.08M | $40.29M | $40.23M | $43.95M | $48.16M | $47.41M | $13.32M | $11.83M | $57.11M | - | - | $14.20M |
| Shareholders' equity | $57.98M | $63.61M | $68.14M | $74.40M | $81.57M | $87.97M | $127.62M | $145.70M | $166.64M | $188.97M | $78.60M | $137.47M |
Cash flow
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$6.09M | -$3.85M | -$8.88M | -$9.75M | -$6.22M | -$4.95M | -$11.34M | -$61.27M | -$18.30M | -$18.24M | -$19.13M | -$22.32M |
| Capital expenditures | $31.0K | - | - | $501.0K | $80.0K | $0 | $0 | $57.0K | $17.0K | $29.0K | $0 | $41.0K |
| Free cash flow | -$6.13M | - | - | -$10.25M | -$6.30M | -$4.95M | -$11.34M | -$61.32M | -$18.31M | -$18.27M | -$19.13M | -$22.36M |
| Investing cash flow | -$31.0K | - | - | -$501.0K | -$80.0K | $0 | $0 | -$57.0K | -$17.0K | -$29.0K | $0 | -$41.0K |
| Financing cash flow | $1.68M | -$16.0K | -$51.0K | -$329.0K | $0 | $0 | $90.0K | $918.0K | $0 | $101.39M | $22.16M | $1.14M |
| Stock-based compensation | $3.48M | $4.07M | $4.07M | $5.37M | $4.40M | $4.58M | $5.22M | $5.74M | $5.61M | $2.60M | $2.33M | $2.13M |
Key ratios
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 1.91 | 2.08 | 2.19 | 2.23 | 2.27 | 2.43 | 9.08 | 11.62 | 3.55 | 4.07 | 1.74 | 9.13 |
Source: XBRL data Filana Therapeutics Inc. files with the SEC, latest filing dated Nov 5, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-7, first reported Aug 9, 2017.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
FLNA peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| FLNA | - | - | -$42.20M | - | $24.2M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.35T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $675.92B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $519.48B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $364.98B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $311.52B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.61B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.31B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $180.22B |
FLNA FAQ
4 questionsIs FLNA profitable?
No. Filana Therapeutics Inc. reported a net loss of $42.20M for the twelve months ended Sep 30, 2026.How much cash and debt does FLNA have?
Filana Therapeutics Inc. reported $46.99M in cash and cash equivalents on its most recent balance sheet in SEC filings.When did FLNA last report financial results?
The latest statements here come from Filana Therapeutics Inc.'s 10-Q filed on Nov 5, 2026, covering the period ended Sep 30, 2026.Where does this FLNA financial data come from?
Quantisnow builds these statements from the structured XBRL data Filana Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.